Interleukin 6 Is a Stronger Predictor of Clinical Events Than High-Sensitivity C-Reactive Protein or D-Dimer during HIV Infection

Journal of Infectious Diseases

Volumn 214, Issue 3, 2016, Pages 408-416

  Borges, Álvaro H ^a   O'Connor, Jemma L ^b   Phillips, Andrew N ^b   Neaton, James D ^c   Grund, Birgit ^d   Neuhaus, Jacqueline ^c   Vjecha, Michael J ^e,f   Calmy, Alexandra ^g   Koelsch, Kersten K ^h,i   Lundgren, Jens D ^a  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

^c Department of Biostatistics   (United States)

^d UNIVERSITY OF MINNESOTA   (United States)

^e Institute for Clinical Research   (United States)

^f VETERANS AFFAIRS MEDICAL CENTER   (United States)

^g GENEVA UNIVERSITY HOSPITALS   (Switzerland)

^h UNIVERSITY OF NEW SOUTH WALES   (Australia)

ⁱ ST VINCENT S HOSPITAL   (Australia)

Author keywords

cancer; cardiovascular disease; D dimer; HIV; hsCRP; IL 6; inflammation

Indexed keywords

C REACTIVE PROTEIN; D DIMER; INTERLEUKIN 6; ANTIFIBRINOLYTIC AGENT; FIBRIN DEGRADATION PRODUCT; FIBRIN FRAGMENT D;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; ARTICLE; CARDIOVASCULAR DISEASE; CONTROLLED STUDY; DEATH; DISEASE COURSE; FEMALE; FOLLOW UP; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; MALIGNANT NEOPLASTIC DISEASE; MORBIDITY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; BLOOD; COHORT ANALYSIS; COMPARATIVE STUDY; EVALUATION STUDY; HIV INFECTIONS; MIDDLE AGED; PATHOLOGY; PROGNOSIS; SENSITIVITY AND SPECIFICITY; SURVIVAL ANALYSIS;

ADULT; ANTIFIBRINOLYTIC AGENTS; C-REACTIVE PROTEIN; COHORT STUDIES; FEMALE; FIBRIN FIBRINOGEN DEGRADATION PRODUCTS; HIV INFECTIONS; HUMANS; INTERLEUKIN-6; MALE; MIDDLE AGED; PROGNOSIS; SENSITIVITY AND SPECIFICITY; SURVIVAL ANALYSIS;

EID: 84981274753     PISSN: 00221899     EISSN: 15376613     Source Type: Journal    
DOI: 10.1093/infdis/jiw173     Document Type: Article

References (48)

1. Rodger AJ, Fox Z, Lundgren JD, et al. Activation and coagulation biomarkers are independent predictors of the development of opportunistic disease in patients with HIV infection. J Infect Dis 2009; 200:973-83.
2. Boulware DR, Hullsiek KH, Puronen CE, et al. Higher levels of CRP, D-dimer, IL-6, and hyaluronic acid before initiation of antiretroviral therapy (ART) are associated with increased risk of AIDS or death. J Infect Dis 2011; 203:1637-46.
3. Borges AH, Weitz JI, Collins G, et al. Markers of inflammation and activation of coagulation are associated with anaemia in antiretroviral-treated HIV disease. AIDS 2014; 28:1791-6.
4. Borges ÁH, Silverberg MJ, Wentworth D, et al. Predicting risk of cancer during HIV infection: the role of inflammatory and coagulation biomarkers. AIDS 2013; 27:1433-41.
5. Duprez DA, Neuhaus J, Kuller LH, et al. Inflammation, coagulation and cardiovascular disease in HIV-infected individuals. PLoS One 2012; 7:e44454.
6. Nordell AD, McKenna M, Borges ÁH, et al. Severity of cardiovascular disease outcomes among patients with HIV is related to markers of inflammation and coagulation. J Am Heart Assoc 2014; 3:e000844.
7. Béténé A, Dooko C, De Wit S, et al. Interleukin-6, high sensitivity C-reactive protein, and the development of type 2 diabetes among HIV-positive patients taking antiretroviral therapy. J Acquir Immune Defic Syndr 2014; 67:538-46.
8. Kuller LH, Tracy R, Belloso W, et al. Inflammatory and coagulation biomarkers and mortality in patients with HIV infection. PLoS Med 2008; 5:e203.
9. Ledwaba L, Tavel JA, Khabo P, et al. Pre-ART levels of inflammation and coagulation markers are strong predictors of death in a South African cohort with advanced HIV disease. PLoS One 2012; 7:e24243.
10. Grund B, Baker JV, Deeks SG, et al. Relevance of Interleukin-6 and D-dimer for serious non-AIDS morbidity and death among HIV-positive adults on suppressive antiretroviral therapy. PLoS One 2016; 11:e0155100.
11. Neaton JD, Neuhaus J, Emery S. Soluble biomarkers and morbidity and mortality among people infected with HIV: summary of published reports from 1997 to 2010. Curr Opin HIV AIDS 2010; 5:480-90.
12. El-Sadr WM, Lundgren JD, Neaton JD, et al. CD4+ count-guided interruption of antiretroviral treatment. N Engl J Med 2006; 355:2283-96.
13. Tanaka T, Kishimoto T. The biology and medical implications of interleukin-6. Cancer Immunol Res 2014; 2:288-94.
14. Heinrich PC, Castell JV, Andus T. Interleukin-6 and the acute phase response. Biochem J 1990; 265:621-36.
15. Adam SS, Key NS, Greenberg CS. D-dimer antigen: current concepts and future prospects. Blood 2009; 113:2878-87.
16. Rajasuriar R, Wright E, Lewin SR. Impact of antiretroviral therapy (ART) timing on chronic immune activation/inflammation and end-organ damage. Curr Opin HIV AIDS 2015; 10:35-42.
17. Duprez DA, Otvos J, Tracy RP, et al. High-density lipoprotein subclasses and non-cardiovascular, noncancer chronic inflammatory-related events versus cardiovascular events: The Multi-Ethnic Study of Atherosclerosis. J Am Heart Assoc 2015; 4:e002295.
18. Abrams D, Lévy Y, Losso MH, et al. Interleukin-2 therapy in patients with HIV infection. N Engl J Med 2009; 361:1548-59.
19. Borges AH, O'Connor JL, Phillips AN, et al. Factors associated with D-dimer levels in HIV-infected individuals. PLoS One 2014; 9:e90978.
20. Lifson AR, Rhame FS, Belloso WH, et al. Reporting and evaluation of HIV-related clinical endpoints in two multicenter international clinical trials. HIV Clin Trials 2006; 7:125-41.
21. Kowalska JD, Friis-Møller N, Kirk O, et al. The Coding Causes of Death in HIV (CoDe) Project: initial results and evaluation of methodology. Epidemiology 2011; 22:516-23.
22. Wei LJ, Lin DY, Weissfeld L. Regression analysis of multivariate incomplete failure time data by modelling marginal distributions. J Am Stat Assoc 1989; 84:1065-73.
23. Interleukin-6 Receptor Mendelian Randomisation Analysis (IL6R MR) Consortium-Hingorani AD, Casas JP. The interleukin-6 receptor as a target for prevention of coronary heart disease: a Mendelian randomisation analysis. Lancet 2012; 379:1214-24.
24. Tian G, Mi J, Wei X, et al. Circulating interleukin-6 and cancer: A meta-analysis using Mendelian randomization. Sci Rep 2015; 5:11394.
25. Zacho J, Tybjaerg-Hansen A, Jensen JS, Grande P, Sillesen H, Nordestgaard BG. Genetically elevated C-reactive protein and ischemic vascular disease. N Engl J Med 2008; 359:1897-08.
26. Wensley F, Gao P, Burgess S, et al. Association between C reactive protein and coronary heart disease: mendelian randomisation analysis based on individual participant data. BMJ 2011; 342:d548.
27. Allin KH, Nordestgaard BG, Zacho J, Tybjaerg-Hansen A, Bojesen SE. C-reactive protein and the risk of cancer: a mendelian randomization study. J Natl Cancer Inst 2010; 102:202-6.
28. Ridker PM, Hennekens CH, Buring JE, Rifai N. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med 2000; 342:836-43.
29. Pai JK, Pischon T, Ma J, et al. Inflammatory markers and the risk of coronary heart disease in men and women. N Engl J Med 2004; 351:2599-610.
30. Reingold J, Wanke C, Kotler D, et al. Association of HIV infection and HIV/HCV coinfection with C-reactive protein levels: the fat redistribution and metabolic change in HIV infection (FRAM) study. J Acquir Immune Defic Syndr 2008; 48:142-8.
31. Neuhaus J, Jacobs DR Jr, Baker JV, et al. Markers of inflammation, coagulation, and renal function are elevated in adults with HIV infection. J Infect Dis 2010; 201:1788-95.
32. Tenorio AR, Zheng Y, Bosch RJ, et al. Soluble markers of inflammation and coagulation but not T-cell activation predict non-AIDS-defining morbid events during suppressive antiretroviral treatment. J Infect Dis 2014; 210:1248-59.
33. Cushman M, Lemaitre RN, Kuller LH, et al. Fibrinolytic activation markers predict myocardial infarction in the elderly. The Cardiovascular Health Study. Arterios-cler Thromb Vasc Biol 1999; 19:493-8.
34. Ford ES, Greenwald JH, Richterman AG, et al. Traditional risk factors and D-dimer predict incident cardiovascular disease events in chronic HIV infection. AIDS 2010; 24:1509-17.
35. Folsom AR, Delaney JA, Lutsey PL, et al. Associations of factor VIIIc, D-dimer, and plasmin-antiplasmin with incident cardiovascular disease and all-cause mortality. Am J Hematol 2009; 84:349-53.
36. Wilson EM, Singh A, Hullsiek KH, et al. Monocyte-activation phenotypes are associated with biomarkers of inflammation and coagulation in chronic HIV infection. J Infect Dis 2014; 210:1396-406.
37. French MA, Cozzi-Lepri A, Arduino RC, Johnson M, Achhra AC, Landay A; INSIGHT SMART Study Group. Plasma levels of cytokines and chemokines and the risk of mortality in HIV-infected individuals: a case-control analysis nested in a large clinical trial. AIDS 2015; 29:847-51.
38. Borges ÁH, O'Connor JL, Phillips AN, et al. Factors associated with plasma IL-6 levels during HIV infection. J Infect Dis 2015; 212:585-95.
39. Il'yasova D, Colbert LH, Harris TB, et al. Circulating levels of inflammatory markers and cancer risk in the health aging and body composition cohort. Cancer Epidemiol Biomarkers Prev 2005; 14:2413-8.
40. Zhang GJ, Adachi I. Serum interleukin-6 levels correlate to tumor progression and prognosis in metastatic breast carcinoma. Anticancer Res 1999; 19:1427-32.
41. Wang TJ, Gona P, Larson MG, et al. Multiple biomarkers for the prediction of first major cardiovascular events and death. N Engl J Med 2006; 355:2631-9.
42. INSIGHT START Study GroupLundgren JD, Babiker AG, et al. Initiation of an-tiretroviral therapy in early asymptomatic HIV infection. N Engl J Med 2015; 373:795-807.
43. Baker JV, Neuhaus J, Duprez D, et al. Changes in inflammatory and coagulation bio-markers: a randomized comparison of immediate versus deferred antiretroviral therapy in patients with HIV infection. J Acquir Immune Defic Syndr 2011; 56:36-43.
44. Jain V, Hartogensis W, Bacchetti P, et al. Antiretroviral therapy initiated within 6 months of HIV infection is associated with lower T-cell activation and smaller HIV reservoir size. J Infect Dis 2013; 208:1202-11.
45. Ridker PM, Danielson E, Fonseca FA, et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med 2008; 359:2195-207.
46. Ridker PM. Moving beyond JUPITER: will inhibiting inflammation reduce vascular event rates? Curr Atheroscler Rep 2013; 15:295.
47. Ridker PM, Thuren T, Zalewski A, Libby P. Interleukin-1βinhibition and the prevention of recurrent cardiovascular events: rationale and design of the Canakinumab Anti-inflammatory Thrombosis Outcomes Study (CANTOS). Am Heart J 2011; 162:597-605.
48. Ridker PM. Testing the inflammatory hypothesis of atherothrombosis: scientific rationale for the cardiovascular inflammation reduction trial (CIRT). J Thromb Haemost 2009; 7:332-9.